Medical imaging can add considerable cost to clinical trials of pharmaceuticals and other life-science products, but the elevated entry price can be offset by imaging’s unique ability to identify appropriate patients and reveal what drugs’ pharmacodynamic properties look like in action.
Such value-adds can “enable imaging biomarkers to increase the probability of success in clinical trials and to evaluate efficacy more rapidly, thereby avoiding further investment in ineffective therapies and promoting therapies that might otherwise have been declared a failure.”
So writes a clinical R&D analyst from the management-consulting firm Beroe Inc. in an opinion piece published online Feb. 6 in Clinical Leader.
Click the link to read the piece:
Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.